Acronym:
UNISoN
ACTRN/NCT /ethics:
Ethics: 316.17
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Kidney | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Kidney |
Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Kidney |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Kidney |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
Phase II sequential treatment trial of single agent nivolumab, then combination Ipilimumab + nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma.
Lay Summary
Sponsor / Cooperative group
ANZUP
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Recruiting | |
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Ganessan Kichenadasse | Recruiting |